Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tumor necrosis factor-alpha (TNF alpha) is one of several pro-inflammatory cytokines that have been implicated in the pathogenesis of Crohn's disease (CD). Treatment with antibodies to TNF alpha has been shown to reduce mucosal inflammation in the disease, promote tissue healing, achieve and maintain remission, improve the CD activity index (CDAI) and improve the quality of life. The first part of this article reviews the role of TNF alpha in CD.

Type

Journal article

Journal

Current opinion in investigational drugs (London, England : 2000)

Publication Date

09/2002

Volume

3

Pages

1297 - 1300

Addresses

Phase 1 Clinical Trials Unit, 119 Looseleigh Lane, Derriford, Plymouth, PL6 5HH, UK.

Keywords

Animals, Humans, Crohn Disease, Tumor Necrosis Factor-alpha